Product Description
Sorrento is developing Resiniferatoxin as a treatment for pain due to Knee Osteoarthritis (OA). (Sourced from: https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-begins-enrollment-phase-2-trial-resiniferatoxin-rtx)
Mechanisms of Action: TRPV1 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sorrento
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Chronic Pain|Pain, Intractable
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| RTX-CAP-201 | P2 |
Suspended |
Pain, Intractable |
2027-06-01 |
71% |
2024-03-20 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
| 2018-000818-37 | P2 |
Completed |
Chronic Pain |
2023-01-26 |
2022-03-13 |
Treatments |